# PanGenetics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pangenetics

- Industry: Pharmaceuticals
- Headquarters: Utrecht, Netherlands
- Website: www.pangenetics.com
- Total disclosed funding: $54M
- Latest round: Series C (Mar 5, 2008)
- Investors on record: 7

## About

PanGenetics specializes in the development and commercialization of innovative biological products for medical applications, enhancing therapeutic capabilities in the healthcare sector.Founded in 1995 and headquartered in Utrecht, Netherlands, PanGenetics focuses on creating advanced biological therapeutics. The company underwent a pivotal change when it was acquired by Abbott Laboratories in November 2009, specifically acquiring the global rights to an antibody to nerve growth factor for USD 170 mn plus earn-out payments. The firm has engaged in a total of four deals to date.Pangenetics.com is currently available for purchase, targeting businesses and individuals aiming to bolster their online presence. The primary offering involves the sale of the domain name for USD 3,595 or a monthly payment option of USD 299.58 over 12 months. This service is designed to assist in establishing brand identity and online visibility, catering to a wide range of users from startups to larger enterprises looking for unique online identifiers across North America and Europe.Revenue for Pangenetics.com is generated through direct domain name sales. Clients can either purchase the domain outright or choose a financing option with monthly payments. The pricing model is straightforward, focusing on a flat rate for domain acquisition, thus ensuring the transaction remains primarily B2C as customers engage directly with the platform to secure their desired domain names.PanGenetics plans to leverage its recent funding to support the development of new biological products and expand its market reach. The latest funding round, resulting in a Trade Sale of USD 190 mn, will enable the company to explore further innovations in therapeutic applications. Additionally, there are plans to target new geographical markets to enhance business operations beyond existing territories, although specific timelines and regions have yet to be detailed.

## Funding rounds

- Series C, Mar 5, 2008, $36M — Index Ventures, Andera Partners, Fortis Private Equity France, Omnes Capital, Forbion, Biogen Idec New Ventures
- Series B, Mar 27, 2006, $16M — Index Ventures, Omnes Capital, Forbion, Capital A
- Seed, Sep 8, 2005, $2M — Index Ventures

## Investors

- Index Ventures (https://capitalatlas.ai/funds/index-ventures) — Seed, Series B, Series C
- Omnes Capital (https://capitalatlas.ai/funds/omnes-capital) — Series B, Series C
- Forbion (https://capitalatlas.ai/funds/forbion) — Series B, Series C
- Capital A — Series B
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series C
- Fortis Private Equity France (https://capitalatlas.ai/funds/fortis-private-equity-france) — Series C
- Biogen Idec New Ventures (https://capitalatlas.ai/funds/biogen-idec-new-ventures) — Series C